Bio-Path Holdings (BPTH) Reports Q3 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results
November 10, 2015 8:55 AM ESTHOUSTON--(BUSINESS WIRE)-- Bio-Path Holdings, Inc., (NASDAQ: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced operational and financial results for the quarter ended September 30, 2015.
The third quarter of 2015 proved to be an exciting time for Bio-Path, as we made significant progress with our lead product candidate, BP1001, said Peter Nielsen, President and Chief Executive Officer of Bio-Path. We reported that one patient with advanced acute myeloid leukemia in our Phase Ib trial achieved complete remission, and another patient... More
